NO20084415L - Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptors - Google Patents
Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptorsInfo
- Publication number
- NO20084415L NO20084415L NO20084415A NO20084415A NO20084415L NO 20084415 L NO20084415 L NO 20084415L NO 20084415 A NO20084415 A NO 20084415A NO 20084415 A NO20084415 A NO 20084415A NO 20084415 L NO20084415 L NO 20084415L
- Authority
- NO
- Norway
- Prior art keywords
- group
- haloc1
- 4alkoxy
- 4alkyl
- 4alkanoyl
- Prior art date
Links
- 102000004073 Dopamine D3 Receptors Human genes 0.000 title abstract 2
- 108090000525 Dopamine D3 Receptors Proteins 0.000 title abstract 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 title 1
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 6
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 6
- -1 haloC1-4alkyl Chemical group 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical group 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000164 antipsychotic agent Substances 0.000 abstract 1
- 229940005529 antipsychotics Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 206010036596 premature ejaculation Diseases 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Den foreliggende oppfinnelse vedrører nyskapende forbindelser av formel (I)' eller et salt derav: hvori G er utvalgt fra en gruppe som består av: fenyl, en 5- eller 6-leddet monosyklisk heteroarylgruppe, eller en 8- til 11-leddet heteroarylbisyklisk gruppe; A er en gruppe P1 eller en gruppe P2 hvori 0 p er et helt tall som spenner fra 0 til 5; R1 er halogen, hydroksy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoksy, haloC1-4alkoksy, C1-4alkanoyl og SF5; eller korresponderer til en gruppe R6; og når p er et helt tall som spenner fra 2 til 5, kan hver R1 være lik eller forskjellig; R2 er hydrogen eller C1-4alkyl; n er 3, 4, 5 eller 6; R6 er en enhet valgt fra gruppen som består av: isoksazolyl, -CH2-N-pyrrolyl, 1,1 dioksido-2-isotiazolidinyl, tienyl, tiazolyl, pyridyl, 2-pyrrolidinonyl og en slik R6 gruppe er valgfritt substituert med en eller to substituenter valgt fra: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoksy, C1-4alkanoyl; R4 er utvalgt innen den gruppen som består av: hydrogen, halogen, hydroksy, cyano, C1-4alkyl, C3-7 cykloalkyl, haloC1-4alkyl, C1-4alkoksy, haloC1-4alkoksy, C1-4alkanoyl og NR'R"; eller R4 er en fenylgruppe, en 5- eller 14-leddet heterosyklisk gruppe; og enhver av slik fenyl- eller heterosyklisk gruppe er valgfritt substituert med 1, 2, 3 eller 4 substituenter valgt fra gruppen som består av: halogen, cyano, C1-4 alkyl, haloC1-4alkyl, C1-4alkoksy, C1-4alkanoyl, haloC1-4alkoksy og SF5; R5 er utvalgt innen den gruppen som består av: hydrogen, halogen, hydroksy, cyano, C1-4alkyl, C3-7cykloalkyl, haloC1-4alkyl, C1-4alkoksy, haloC1-4alkoksy, C1-4alkanoyl og NR'R"; eller R5 er en fenylgruppe, en 5- til 14-leddet heterosyklisk gruppe; og enhver av slike fenyl- eller heterosykliske grupper er valgfritt substituert med 1, 2, 3 eller 4 substituenter valgt fra gruppen som består av: halogen, cyano, C1-4 alkyl, haloC1-4alkyl, C1-4alkoksy, C1-4alkanoyl, haloC1-4alkoksy og SF5; R7 er hydrogen eller C1-2alkyl; R' er H, C1-4alkyl eller C1-4alkanoyl; R" er definert som W; R' og R" tatt sammen med det sammenbindende nitrogenatom kan danne en 5- eller 6-leddet mettet eller umettet heterosyklisk ring; hvori minst en av R4 og R5 er hydrogen; og hvori bare en R2-gruppe kan være forskjellig fra hydrogen; fremgangsmåter for deres fremstilling, mellomprodukter benyttet i disse fremgangsmåter, farmasøytiske preparater som inneholder dem og deres anvendelse i terapi, som modulatorer for dopamin D3 reseptorer, for eksempel for å behandle stoffavhengighet, som antipyskotiske midler, for å behandle lidelser i det obsessive kompulsive spekter, eller prematur ejakulasjon.The present invention relates to novel compounds of formula (I) or a salt thereof: wherein G is selected from a group consisting of: phenyl, a 5- or 6-membered monocyclic heteroaryl group, or an 8- to 11-membered heteroarylbicyclic group ; A is a group P1 or a group P2 wherein 0 p is an integer ranging from 0 to 5; R1 is halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl and SF5; or corresponds to a group R6; and when p is an integer ranging from 2 to 5, each R1 may be the same or different; R 2 is hydrogen or C 1-4 alkyl; n is 3, 4, 5 or 6; R6 is a moiety selected from the group consisting of: isoxazolyl, -CH2-N-pyrrolyl, 1,1 dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl, 2-pyrrolidinonyl and such R6 group is optionally substituted by one or two substituents selected from: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl; R4 is selected from the group consisting of: hydrogen, halogen, hydroxy, cyano, C1-4alkyl, C3-7 cycloalkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl and NR'R "; or R4 is a phenyl group, a 5- or 14-membered heterocyclic group, and any such phenyl or heterocyclic group is optionally substituted with 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4 alkyl , haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl, haloC1-4alkoxy and SF5; R5 is selected from the group consisting of: hydrogen, halogen, hydroxy, cyano, C1-4alkyl, C3-7cycloalkyl, haloC1-4alkyl, C1 -4alkoxy, haloC1-4alkoxy, C1-4alkanoyl and NR'R "; or R 5 is a phenyl group, a 5- to 14-membered heterocyclic group; and any of such phenyl or heterocyclic groups are optionally substituted with 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4 alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl, haloC1 -4alkoxy and SF5; R 7 is hydrogen or C 1-2 alkyl; R 1 is H, C 1-4 alkyl or C 1-4 alkanoyl; R "is defined as W; R 'and R" taken together with the bonding nitrogen atom may form a 5- or 6-membered saturated or unsaturated heterocyclic ring; wherein at least one of R4 and R5 is hydrogen; and wherein only one R 2 group may be different from hydrogen; methods for their preparation, intermediates used in these methods, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3 receptors, for example to treat drug dependence, as antipsychotics, to treat disorders of the obsessive compulsive spectrum, or premature ejaculation.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0607892A GB0607892D0 (en) | 2006-04-03 | 2006-04-03 | Novel compounds |
| PCT/EP2007/053074 WO2007113232A1 (en) | 2006-04-03 | 2007-03-30 | Azabicyclo [3. 1. 0] hexyl derivatives as modulators of dopamine d3 receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20084415L true NO20084415L (en) | 2008-12-08 |
Family
ID=36580997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20084415A NO20084415L (en) | 2006-04-03 | 2008-10-21 | Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptors |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN101460485A (en) |
| GB (1) | GB0607892D0 (en) |
| NO (1) | NO20084415L (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012000657A2 (en) * | 2009-06-26 | 2016-11-16 | Panacea Biotec Ltd | new azabicylhexanes |
| CN116655604B (en) * | 2022-02-17 | 2025-09-16 | 苏州第四制药厂有限公司 | Synthesis method of Pa Luo Weide |
-
2006
- 2006-04-03 GB GB0607892A patent/GB0607892D0/en not_active Ceased
-
2007
- 2007-03-30 CN CNA2007800206464A patent/CN101460485A/en active Pending
-
2008
- 2008-10-21 NO NO20084415A patent/NO20084415L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101460485A (en) | 2009-06-17 |
| GB0607892D0 (en) | 2006-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20064309L (en) | Azabicyclo (3.1.0) hexane derivatives useful as modulators for dopamine D3 receptors | |
| PE20141827A1 (en) | PROTEIN INHIBITORS KINASES | |
| PE20090905A1 (en) | HETEROCYCLIC AMIDAS COMPOUNDS AS PROTEINKINASE INHIBITORS | |
| MY152805A (en) | Benzazepine derivatives useful as vasopressin antagonists | |
| NO20091678L (en) | Modulators of the glucocorticoid receptor, AP-1, and / or NF-kappaB activity and their use | |
| NO20083582L (en) | Pyridine-2-carboxamide derivatives | |
| EA201101566A1 (en) | IMIDAZOL DERIVATIVES AND THEIR APPLICATION AS CYLIN-dependent KINAZ MODULATORS | |
| WO2008057855A3 (en) | Heterocyclic compounds as modulators of glucocorticoid receptor, ap-i, and/or np-kappa-b activity | |
| AR074596A1 (en) | DERIVATIVES OF (3-OXO) PIRIDAZIN-4-ILUREA | |
| PE20171057A1 (en) | SPIRODIAMINE DERIVATIVES AS INHIBITORS OF ALDOSTERONE SYNTHASE | |
| NO20073729L (en) | Heterocyclic Compounds as CCR2B Antagonists | |
| PE20080275A1 (en) | DERIVATIVES OF 5H-BENZO [4,5] CYCLOHEPTA [1,2] PYRIDINE AS INHIBITORS OF TYROSINE KINASE | |
| ATE487715T1 (en) | TRIAZOLE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | |
| EA201200602A1 (en) | INDAZOLES AND PYRAZOLOPIRIDIN AS ANTAGONISTS OF CCR1 RECEPTOR | |
| MX2009010461A (en) | Quinolines and their therapeutic use. | |
| DE602006019221D1 (en) | OF DOPAMINE D3 RECEPTORS | |
| BRPI0519292A2 (en) | organic compounds | |
| DE602006011725D1 (en) | 3-TRIAZOLYL THIOALKYL-3-AZABICYCLO Ä3.1.0ÜHEXANE AND THEIR USE AS LIGANDS OF DOPAMINE D3 RECEPTOR | |
| PE20070212A1 (en) | 1,4-DIHYDROPYRIDINE-CONDENSED HETEROCYCLES, PROCESSES TO PREPARE THE SAME, USE AND COMPOSITIONS CONTAINING THEM | |
| ATE541839T1 (en) | PYRROLIDINIUM DERIVATIVES AS M3 MUSCARINIC RECEPTORS | |
| IN2012DN02871A (en) | ||
| PE20091890A1 (en) | 3-PHENYLPYRAZOLE [5,1-b] THIAZOLE COMPOUNDS | |
| NO20084415L (en) | Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptors | |
| ATE396183T1 (en) | CHROMEAND DERIVATIVES AND THEIR USE AS LIGANDS OF THE 5-HT RECEPTOR | |
| NO20081529L (en) | naphthyridine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |